Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Treatment with bevacizumab plus IFN and sunitinib has clinically relevant and statistically significant advantages over treatment with IFN alone in patients with metastatic RCC. In people with three of six risk factors for poor prognosis, temsirolimus had clinically relevant advantages over treatment with IFN, and sorafenib tosylate was superior to best supportive care as second-line therapy. The frequency of adverse events associated with bevacizumab plus IFN, sunitinib and temsirolimus was comparable with that seen with IFN, although the adverse event profile is different. Treatment with sorafenib was associated with a significantly increased frequency of hypertension and hand-foot syndrome. Estimates from the PenTAG model suggested that none of the interventions would be considered cost-effective at a willingness-to-pay threshold of 30,000 pounds per QALY
1-184
Thompson Coon, J.
361482fe-af95-4c17-a1fa-0fe49af0d237
Hoyle, M.
af04245a-4935-4c89-93d0-2aefaad30ed2
Green, C.
a4440ea4-08aa-4bde-810e-9b615150e39e
Liu, Z.
f2d813f1-8806-4fd5-a719-2e9357f2453f
Welch, K.
2603c214-aace-486f-8723-b006873248a5
Moxham, T.
a98c30c4-b839-4028-9539-b9367d8f9dc0
Stein, K.
5f0b93b6-a47b-4976-b813-f498931d5286
January 2010
Thompson Coon, J.
361482fe-af95-4c17-a1fa-0fe49af0d237
Hoyle, M.
af04245a-4935-4c89-93d0-2aefaad30ed2
Green, C.
a4440ea4-08aa-4bde-810e-9b615150e39e
Liu, Z.
f2d813f1-8806-4fd5-a719-2e9357f2453f
Welch, K.
2603c214-aace-486f-8723-b006873248a5
Moxham, T.
a98c30c4-b839-4028-9539-b9367d8f9dc0
Stein, K.
5f0b93b6-a47b-4976-b813-f498931d5286
Thompson Coon, J., Hoyle, M., Green, C., Liu, Z., Welch, K., Moxham, T. and Stein, K.
(2010)
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Health Technology Assessment, 14 (2), .
(doi:10.3310/hta14020).
(PMID:20028613)
Abstract
Treatment with bevacizumab plus IFN and sunitinib has clinically relevant and statistically significant advantages over treatment with IFN alone in patients with metastatic RCC. In people with three of six risk factors for poor prognosis, temsirolimus had clinically relevant advantages over treatment with IFN, and sorafenib tosylate was superior to best supportive care as second-line therapy. The frequency of adverse events associated with bevacizumab plus IFN, sunitinib and temsirolimus was comparable with that seen with IFN, although the adverse event profile is different. Treatment with sorafenib was associated with a significantly increased frequency of hypertension and hand-foot syndrome. Estimates from the PenTAG model suggested that none of the interventions would be considered cost-effective at a willingness-to-pay threshold of 30,000 pounds per QALY
This record has no associated files available for download.
More information
Published date: January 2010
Organisations:
Faculty of Medicine
Identifiers
Local EPrints ID: 351812
URI: http://eprints.soton.ac.uk/id/eprint/351812
ISSN: 1366-5278
PURE UUID: 9cc9cb83-a0a3-487d-a92d-4737912551b0
Catalogue record
Date deposited: 25 Apr 2013 11:05
Last modified: 14 Mar 2024 13:43
Export record
Altmetrics
Contributors
Author:
J. Thompson Coon
Author:
M. Hoyle
Author:
C. Green
Author:
Z. Liu
Author:
K. Welch
Author:
T. Moxham
Author:
K. Stein
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics